COVID-19
Conditions
Interventions
None listed
Sponsors
Shionogi & Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Employee and their family members in Shionogi & Co. Ltd. (including its group companies) and other companies who can perform evaluation by application by themselves. 2) Employee and their family members in Shionogi & Co. Ltd. (including its group companies) and other companies who consented to this study by their own will with substantial understanding of this research by reading through ICF. 3) Employee and their family members in Shionogi & Co. Ltd. (including its group companies) and other companies with either of the following condition: (A) Those who are vaccinated for SARS-CoV-2. The 1st vaccination was performed less than 6 months before of obtaining their consent. (B) Those who have not been vaccinated for SARS-CoV-2. They are not applied for or will not be vaccinated by November 2021. 4) Those who can download the application for this study and enter the data through the application.
Exclusion criteria
Exclusion criteria: Those who do not consent to this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SARS-CoV-2 positive rate at 6-months | — |
Secondary
| Measure | Time frame |
|---|---|
| The following endpoints at 3, 6, 9, and 12 months: - SARS-CoV-2 positive rate (except for 6 month as this is defined as the primary endpoint) - COVID-19 incidence rate - Incidence rate of COVID-19-related symptoms - Rate of subjects in each COVID-19 infection severity - Household transmission rate - Incidence rate of symptoms which were observed after SARS-CoV-2 vaccination | — |
Countries
Japan
Contacts
Public ContactShintaro Tanaka
Shionogi & Co., Ltd. Medical Affairs Department
Outcome results
None listed